Articles with public access mandates - Andreas BehrenLearn more
Not available anywhere: 9
In Situ Single Cell Proteomics Reveals Circulating Tumor Cell Heterogeneity during Treatment
KK Reza, S Dey, A Wuethrich, J Wang, A Behren, F Antaw, Y Wang, ...
ACS nano 15 (7), 11231-11243, 2021
Mandates: US National Institutes of Health, Australian Research Council, National …
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial–Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity
J Yao, OL Caballero, Y Huang, C Lin, D Rimoldi, A Behren, JS Cebon, ...
Cancer immunology research 4 (6), 552-561, 2016
Mandates: US National Institutes of Health
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition
MC Andrews, A Behren, F Chionh, J Mariadason, LJ Vella, H Do, ...
J Clin Oncol 31 (35), e448-e451, 2013
Mandates: National Health and Medical Research Council, Australia, Department of …
SERS multiplex profiling of melanoma circulating tumor cells for predicting the response to immune checkpoint blockade therapy
J Li, A Wuethrich, Z Zhang, J Wang, LL Lin, A Behren, Y Wang, M Trau
Analytical Chemistry 94 (42), 14573-14582, 2022
Mandates: US National Institutes of Health, Australian Research Council, National …
Targeting butyrophilins for cancer immunotherapy
M Rigau, AP Uldrich, A Behren
Trends in immunology 42 (8), 670-680, 2021
Mandates: Australian Research Council, German Research Foundation
Evolving role of tumor antigens for future melanoma therapies
MC Andrews, K Woods, J Cebon, A Behren
Future Oncology 10 (8), 1457-1468, 2014
Mandates: National Health and Medical Research Council, Australia
Methylation dependent gold adsorption behaviour identifies cancer derived extracellular vesicular DNA
AAI Sina, TY Lin, R Vaidyanathan, Z Wang, S Dey, J Wang, A Behren, ...
Nanoscale Horizons 5 (9), 1317-1323, 2020
Mandates: US National Institutes of Health, Australian Research Council, National …
TCF-1 limits intraepithelial lymphocyte antitumor immunity in colorectal carcinoma
MH Yakou, S Ghilas, K Tran, Y Liao, S Afshar-Sterle, A Kumari, K Schmid, ...
Science Immunology 8 (88), eadf2163, 2023
Mandates: National Health and Medical Research Council, Australia
Durable response to combination immunotherapy using Nivolumab and Ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour
O Klein, J Palmer, A Behren, J Cebon, D Kee
European Journal of Cancer, 2023
Mandates: Medical Research Future Fund, Australia
Available somewhere: 55
Pan-cancer analysis of whole genomes.
S Hirano, L Yang, M Juul, CA Purdie, BP O'Neill, R Kabbe, ...
Nature 578 (DKFZ-2020-01051), 82-93, 2020
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
Whole-genome landscapes of major melanoma subtypes
NK Hayward, JS Wilmott, N Waddell, PA Johansson, MA Field, K Nones, ...
Nature 545 (7653), 175-180, 2017
Mandates: US Department of Energy, National Health and Medical Research Council …
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ...
Nature 549 (7670), 101-105, 2017
Mandates: US National Institutes of Health, National Health and Medical Research …
Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells
M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ...
Science 367 (6478), 2020
Mandates: US National Institutes of Health, Australian Research Council, National …
A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients
J Cursons, F Souza-Fonseca-Guimaraes, M Foroutan, A Anderson, ...
Cancer immunology research 7 (7), 1162-1174, 2019
Mandates: National Health and Medical Research Council, Australia
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
SCH Tsao, J Weiss, C Hudson, C Christophi, J Cebon, A Behren, ...
Scientific reports 5 (1), 1-11, 2015
Mandates: National Health and Medical Research Council, Australia
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial
O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ...
Jama Oncology 6 (9), 1405-1409, 2020
Mandates: US National Institutes of Health, Medical Research Future Fund, Australia
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
EF Lee, TJ Harris, S Tran, M Evangelista, S Arulananda, T John, ...
Cell Death & Disease 10 (5), 342, 2019
Mandates: Australian Research Council, National Health and Medical Research Council …
BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage
VJ Mar, SQ Wong, J Li, RA Scolyer, C McLean, AT Papenfuss, RW Tothill, ...
Clinical Cancer Research 19 (17), 4589-4598, 2013
Mandates: National Health and Medical Research Council, Australia
Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers
O Klein, D Kee, B Markman, M Michael, CR Underhill, MS Carlino, ...
Clinical Cancer Research, 2020
Mandates: US National Institutes of Health
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
A Jayachandran, M Anaka, P Prithviraj, C Hudson, SJ McKeown, PH Lo, ...
Oncotarget 5 (14), 5782, 2014
Mandates: National Health and Medical Research Council, Australia
Publication and funding information is determined automatically by a computer program